DeepMed Research

Chong Kun Dang Pharmaceutical Corp.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-01-01

Employees: 2.3K

Market Cap: -

Website: http://www.ckdpharm.com

Clinical Trials

Efficacy and Safety of TELMINUVO to Stage 2 Hypertension

Phase 3

Conditions: Hypertension

Interventions: Drug: TELMINUVO Tab. (80/2.5mg)
Drug: S-amlodipine 2.5mg
Drug: TELMINUVO Tab. (80/5mg)
Drug: S-amlodipine 5mg

First Posted Date: 2013-11-14

Last Posted Date: 2013-11-14

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 200

Registration Number: NCT01983735

Locations: 🇰🇷
The catholic university of Korea Seoul St. Mary's hospital, Seoul, Korea, Republic of

Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin

Phase 3

Conditions: Mixed Hyperlipidemia

Interventions: Drug: Atorvastatin 20mg
Other: Placebo (Fenofibrate 160 mg)
Drug: Fenofibrate 160mg

First Posted Date: 2013-10-08

Last Posted Date: 2015-02-04

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 476

Registration Number: NCT01956201

Locations: 🇰🇷
Chonnam National University Hospital, Gwangju, Korea, Republic of
🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷
Daegu Catholic University Medical Center, Daegu, Korea, Republic of

and more 27 locations

Bioequivalence Study of Tacrobell Capsule 1mg to Prograf Capsule 1mg

Not Applicable

Completed

Conditions: Immunosuppression

Interventions: Drug: Tacrobell capsule 1mg
Drug: Prograf capsule 1mg

First Posted Date: 2013-07-29

Last Posted Date: 2014-07-23

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 50

Registration Number: NCT01910077

Locations: 🇰🇷
Seoul national university hospital, Seoul, Korea, Republic of

The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD

Phase 4

Completed

Conditions: Reflux Esophagitis

Interventions: Drug: Newrabell® Tablet 10mg

First Posted Date: 2013-05-22

Last Posted Date: 2015-09-24

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 39

Registration Number: NCT01860482

Locations: 🇰🇷
Chonnam National University Hwasun Hospital, Gwangju, Hwasun-eup,Hwasun-gun, Korea, Republic of
🇰🇷
Chonnam National University Hospital, Gwangju, Donggu, Jebongro, Korea, Republic of

Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipine

Phase 1

Completed

Conditions: Essential Hypertension
Hyperlipidemia

Interventions: Drug: Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg
Drug: Telmisartan 80mg and S-amlodipine 5mg

First Posted Date: 2013-04-29

Last Posted Date: 2013-08-01

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 24

Registration Number: NCT01842230

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin.

Phase 1

Completed

Conditions: Essential Hypertension
Hyperlipidemia

Interventions: Drug: Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg
Drug: atorvastatin 40mg

First Posted Date: 2013-04-29

Last Posted Date: 2013-08-01

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 24

Registration Number: NCT01842256

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

Evaluate the Efficacy and Safety of My-Rept® Tablet vs. My-Rept® Capsule in Combination With Tacrolimus in Kidney Transplant Patients

Phase 4

Completed

Conditions: Kidney Transplantation

Interventions: Drug: Mycophenolate Mofetil 250mg
Drug: Mycophenolate Mofetil 500mg

First Posted Date: 2013-04-29

Last Posted Date: 2015-08-19

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 156

Registration Number: NCT01842269

Locations: 🇰🇷
Kandong Sacred Heart Hospital, Seoul, Korea, Republic of
🇰🇷
Chunbuk National University Hospital, Chonju, Korea, Republic of
🇰🇷
Wonkwang University School of Medical & Hospital, Iksan, Korea, Republic of

and more 8 locations

Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32mg and Dilatrend Tablet 25mg

Phase 1

Conditions: Congestive Heart Failure
Essential Hypertension
Chronic Stable Angina

Interventions: Drug: Dilatrend SR capsule 32mg
Drug: Dilatrend IR tablet 25mg

First Posted Date: 2013-03-28

Last Posted Date: 2013-04-01

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 48

Registration Number: NCT01819870

Locations: 🇰🇷
Kyungpook National University Hospital Clinical Trial Center, Daegu, eok-dong 2(i)-ga Jung-gu, Korea, Republic of

The Study to Evaluate Efficacy and Safety of MY-REPT Capsule in Primary, Liver Transplantation Recipients (MYLT1)

Phase 4

Conditions: Evidence of Liver Transplantation

Interventions: Drug: Mycophenolate mofetil

First Posted Date: 2013-01-11

Last Posted Date: 2013-11-07

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 120

Registration Number: NCT01766518

Locations: 🇰🇷
Seoul ST Mary's Hospital, Seoul, Korea, Republic of
🇰🇷
Asan medical center, Seoul, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

The Study to Evaluate Efficacy and Safety of Candesartan vs Losartan in Hypertension With Heart Failure (HONOR)

Phase 4

Terminated

Conditions: Hypertension

Interventions: Drug: Candemore tablet
Drug: Cozzar tablet

First Posted Date: 2013-01-11

Last Posted Date: 2014-03-14

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 32

Registration Number: NCT01766505

Locations: 🇰🇷
Presbyterian Medical Center, Chunju, Korea, Republic of
🇰🇷
Chunbuk National University Hospital, Chonju, Korea, Republic of
🇰🇷
Chungnam national university hospital, Daejeon, Korea, Republic of

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy